Setterwalls advises Alligator Bioscience in connection with rights issue of approximately SEK 150 million

Setterwalls advises Alligator Bioscience AB (“Alligator”), listed on Nasdaq Stockholm, in connection with a rights issue of units of approximately SEK 150 million with an over-allotment issue of up to an additional approximately SEK 100 million.

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s shares are listed on Nasdaq Stockholm, and the company is headquartered in Lund, Sweden.